Biosynex SA (EPA: ALBIO)
France
· Delayed Price · Currency is EUR 1.296
-0.054 (-4.00%)
Dec 20, 2024, 4:14 PM CET
Biosynex Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 104.07 | 92.98 | 196.59 | 382.53 | 153.9 | 35.17 | Upgrade
|
| Revenue | 104.07 | 92.98 | 196.59 | 382.53 | 153.9 | 35.17 | Upgrade
|
| Revenue Growth (YoY) | 7.29% | -52.70% | -48.61% | 148.57% | 337.54% | 12.38% | Upgrade
|
| Cost of Revenue | 49.01 | 43.85 | 94.26 | 176.12 | 84.58 | 15.73 | Upgrade
|
| Gross Profit | 55.06 | 49.13 | 102.33 | 206.41 | 69.32 | 19.44 | Upgrade
|
| Selling, General & Admin | 42.24 | 36.06 | 21.44 | 17.25 | 14.58 | 8.18 | Upgrade
|
| Other Operating Expenses | 17.07 | 24.6 | 25.64 | 41.9 | 2.36 | 8.59 | Upgrade
|
| Operating Expenses | 82.49 | 85.28 | 63.44 | 65.76 | 23.58 | 17.84 | Upgrade
|
| Operating Income | -27.43 | -36.15 | 38.88 | 140.65 | 45.73 | 1.6 | Upgrade
|
| Interest Expense | -2.77 | -2.08 | -0.5 | -0.35 | -0.22 | -0.16 | Upgrade
|
| Earnings From Equity Investments | -0.05 | -1.51 | -5.57 | -2.68 | -0.85 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 2.01 | 3 | 0.75 | 0.35 | -0.13 | 0.07 | Upgrade
|
| EBT Excluding Unusual Items | -28.24 | -36.74 | 33.56 | 137.98 | 44.53 | 1.51 | Upgrade
|
| Impairment of Goodwill | -9.61 | -1.26 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -3.82 | -3.98 | -3.45 | - | 0.06 | -0.07 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -0.07 | Upgrade
|
| Other Unusual Items | 1.06 | 2.3 | -5.93 | -1.04 | -1.07 | -0.13 | Upgrade
|
| Pretax Income | -40.61 | -39.68 | 24.18 | 136.94 | 43.52 | 1.25 | Upgrade
|
| Income Tax Expense | -1.89 | -2.56 | 8.57 | 32.94 | 12.15 | 0.15 | Upgrade
|
| Earnings From Continuing Operations | -38.72 | -37.12 | 15.61 | 104 | 31.37 | 1.1 | Upgrade
|
| Minority Interest in Earnings | 0.25 | 0.18 | 0.04 | - | - | - | Upgrade
|
| Net Income | -38.48 | -36.95 | 15.66 | 104 | 31.37 | 1.1 | Upgrade
|
| Net Income to Common | -38.48 | -36.95 | 15.66 | 104 | 31.37 | 1.1 | Upgrade
|
| Net Income Growth | - | - | -84.95% | 231.54% | 2756.89% | 102.26% | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 10 | 10 | 9 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 10 | 10 | 9 | 9 | Upgrade
|
| Shares Change (YoY) | 9.49% | 3.96% | -0.86% | 16.59% | -2.45% | - | Upgrade
|
| EPS (Basic) | -3.47 | -3.45 | 1.53 | 10.08 | 3.52 | 0.12 | Upgrade
|
| EPS (Diluted) | -3.47 | -3.45 | 1.52 | 10.01 | 3.52 | 0.12 | Upgrade
|
| EPS Growth | - | - | -84.82% | 184.38% | 2833.33% | 101.93% | Upgrade
|
| Free Cash Flow | -20.56 | -49.2 | -32.83 | 90.82 | 22.52 | - | Upgrade
|
| Free Cash Flow Per Share | -1.86 | -4.59 | -3.19 | 8.74 | 2.53 | - | Upgrade
|
| Dividend Per Share | - | - | - | 2.000 | 0.200 | - | Upgrade
|
| Dividend Growth | - | - | - | 900.00% | - | - | Upgrade
|
| Gross Margin | 52.91% | 52.84% | 52.05% | 53.96% | 45.04% | 55.28% | Upgrade
|
| Operating Margin | -26.36% | -38.88% | 19.78% | 36.77% | 29.72% | 4.54% | Upgrade
|
| Profit Margin | -36.97% | -39.74% | 7.96% | 27.19% | 20.38% | 3.12% | Upgrade
|
| Free Cash Flow Margin | -19.76% | -52.91% | -16.70% | 23.74% | 14.63% | - | Upgrade
|
| EBITDA | -20.24 | -29.82 | 60.25 | 142.69 | 52.98 | 2.67 | Upgrade
|
| EBITDA Margin | -19.45% | -32.07% | 30.65% | 37.30% | 34.43% | 7.58% | Upgrade
|
| D&A For EBITDA | 7.19 | 6.33 | 21.36 | 2.04 | 7.25 | 1.07 | Upgrade
|
| EBIT | -27.43 | -36.15 | 38.88 | 140.65 | 45.73 | 1.6 | Upgrade
|
| EBIT Margin | -26.36% | -38.88% | 19.78% | 36.77% | 29.72% | 4.54% | Upgrade
|
| Effective Tax Rate | - | - | 35.44% | 24.05% | 27.92% | 12.32% | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 36.13 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.